Diovan (valsartan)

Ciba Pharmaceuticals

Approval Status
Approved January 1997

Treatment for

Possible similar drugs
Diovan; Diovan HCT

Cardiovascular / Cardiology , Diabetes / Endocrinology

Diovan has been approved as the newest entry to a novel class of antihypertensive drugs, the angiotensin II receptor blockers (ARBs). Diovan is indicated for the first-line treatment of hypertension. It offers blood pressure control comparable to current leading antihypertensive therapies (lisinopril and enalapril) and an outstanding side-effect profile.

Diovan is a first-line therapy, which has a recommended starting dose of 80 mg once daily and will be available by prescription in capsule form.

As with other drugs that work in the renin-angiotensin system, Diovan therapy should be discontinued as soon as pregnancy is detected.

Diovan works by selectively blocking the angiotensin II hormone from binding to the AT1-receptor, located in many different tissues such as vascular smooth muscle. The blocking of angiotensin II results in dilation of blood vessels, thereby lowering blood pressure.

Diovan (valsartan) Drug Information

The Diovan (valsartan) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top